Perrigo Co. PLC CEO John Hendrickson used the pulpit of what was likely his final earnings briefing at the helm of the OTC private label leader to urge FDA and manufacturers to make more Rx drug ingredients available nonprescription.
During Perrigo’s second-quarter earnings briefing on Aug. 10, Hendrickson, who will resign from his post when a successor is appointed,...